<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598857</url>
  </required_header>
  <id_info>
    <org_study_id>AN-VAS3321</org_study_id>
    <nct_id>NCT01598857</nct_id>
  </id_info>
  <brief_title>BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis</brief_title>
  <acronym>BIANCA-SC</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anthera Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when
      taken with methotrexate in the induction of remission in ANCA-Associated Small Vessel
      Vasculitis.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2014</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction of clinical remission</measure>
    <time_frame>24 weeks</time_frame>
    <description>Clinical remission includes the ability to taper corticosteroids.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to complete remission</measure>
    <time_frame>Various timepoints to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Various timepoints to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to taper corticosteroids</measure>
    <time_frame>Various timepoints to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline BVAS/WG score</measure>
    <time_frame>Various timepoints to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>Various timepoints to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare biomarker changes from baseline</measure>
    <time_frame>Various timepoints to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Granulomatosis With Polyangiitis</condition>
  <condition>Microscopic Polyangiitis</condition>
  <arm_group>
    <arm_group_label>Blisibimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blisibimod</intervention_name>
    <arm_group_label>Blisibimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older (male or female).

          2. Granulomatosis with polyangiitis (GPA, or Wegener's granulomatosis) or microscopic
             polyangiitis (MPA) according to the definitions of the American College of
             Rheumatology and Chapel Hill Consensus Conference.

          3. Active GPA or MPA disease at screening.

          4. Positive for either PR3-ANCA or MPO-ANCA at screening.

          5. Subject willing to initiate corticosteroids and methotrexate (MTX) if not already on
             corticosteroids and/or MTX at baseline.

          6. Clinical intention to prescribe MTX therapy for treatment of GPA or MPA.

        Exclusion Criteria:

          1. Diagnosed with Churg Strauss syndrome.

          2. Severe GPA or MPA disease that would conventionally be treated with cyclophosphamide.

          3. Nursing or pregnant.

          4. Active systemic infection or deep-space infection.

          5. Active hepatitis B, active hepatitis C or a documented history of HIV, hepatitis B, or
             hepatitis C.

          6. Liver disease.

          7. History of documented anti-glomerular basement membrane (GBM) disease.

          8. Malignancy within the past 5 years.

          9. History of active tuberculosis (TB) or history of TB infection.

         10. Anemia, neutropenia, or thrombocytopenia.

         11. Serum creatinine level greater than 2.5 mg/dL.

         12. Prior administration of a B-cell modulating therapy other than rituximab.

         13. Subject has not yet completed at least 3 months or 5 half-lives (whichever is longer)
             since ending other investigational study.

         14. History of congenital immunodeficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <last_update_submitted>July 28, 2015</last_update_submitted>
  <last_update_submitted_qc>July 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>granulomatosis with polyangiitis</keyword>
  <keyword>microscopic polyangiitis</keyword>
  <keyword>anti-neutrophil cytoplasmic antibodies</keyword>
  <keyword>ANCA-associated vasculitis</keyword>
  <keyword>Wegener Granulomatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

